Table 4.
Comparison between patients with HRs to ICM and patients with HRs to GBCM.
| Positive STs 1 | Negative STs | p-Value | ||
|---|---|---|---|---|
| Patients | (n°) | 30 | 320 | |
| Time interval (months) between reaction and STs | (median, range) | 22 (2–10) | 66 (3–84) | <0.01 * |
| HRs 2 to ICM 3 | (n°) | 22 | 267 | |
| IHRs | (n°, %) | 19 (86.3) | 207 (77.5) | N.S. ** |
| NIHRs | (n°, %) | 3 (13.6) | 60 (22.5) | N.S. ** |
| culprit ICM | ** | |||
| iopromide | (n°, %) | 6 (27.3) | 44 (16.5) | N.S. |
| iomeprol | (n°, %) | 10 (45.4) | 42 (15.7) | <0.01 |
| iopamidol | (n°, %) | 3 (13.6) | 4 (1.5) | <0.05 |
| iohexol | (n°, %) | - | 8 (3) | - |
| iobitridol | (n°, %) | 1 (4.5) | 3 (1.1) | N.S. |
| iodixanol | (n°, %) | - | 5 (1.9) | - |
| ioversol | (n°, %) | - | 1 (0.4) | - |
| unknown culprit ICM | (n°, %) | 2 (9.1) | 160 (59.9) | <0.01 |
| HRs to GBCM 4 | (n°) | 8 | 64 | |
| IHRs | (n°, %) | 8 (100) | 54 (84.4) | N.S. ** |
| NIHRs | (n°, %) | 0 (0) | 60 (15.6) | N.S. ** |
| culprit GBCM | ** | |||
| gadobutrol | (n°, %) | 1 (14.3) | 3 (4.7) | N.S. |
| gadobenic acid | (n°, %) | 3 (42.8) | 3 (4.7) | <0.05 |
| gadoteridol | (n°, %) | - | 7 (10.9) | - |
| gadopentetic acid | (n°, %) | - | 1 (1.6) | - |
| gadoteric acid | (n°, %) | 1 (14.3) | 5 (7.8) | N.S. |
| gadoxetic acid | (n°, %) | 1 (14.3) | - | - |
| unknown culprit GBCM | (n°, %) | 2 (25) | 45 (70.3) | <0.01 |
1: STs = skin tests; 2: HRs = hypersensitivity reactions; 3: ICM = iodinated contrast media; 4: GBCM = gadolinium-based contrast media; *: Mann–Whitney U test; **: Fisher exact test.